Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $5.58 USD
Change Today -0.21 / -3.63%
Volume 824.3K
PTX On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

pernix therapeutics holdings (PTX) Snapshot

Open
$5.80
Previous Close
$5.79
Day High
$5.84
Day Low
$5.44
52 Week High
03/11/15 - $12.88
52 Week Low
06/24/15 - $5.06
Market Cap
243.0M
Average Volume 10 Days
1.7M
EPS TTM
$-1.16
Shares Outstanding
43.5M
EX-Date
09/8/01
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PERNIX THERAPEUTICS HOLDINGS (PTX)

Related News

No related news articles were found.

pernix therapeutics holdings (PTX) Related Businessweek News

No Related Businessweek News Found

pernix therapeutics holdings (PTX) Details

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells branded and generic pharmaceutical products. The company’s product include CEDAX, an oral cephalosporin used for the treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis, middle ear infection due to haemophilus influenza, or streptococcus pyogene; Zutripro, Rezira, and Vituz for the relief of cough and nasal congestion; and OMECLAMOX-PAK a gastroenterology product. Its products also comprise Treximet, a medication indicated for the acute treatment of migraine attacks in adults; Silenor, a medication indicated for the treatment of insomnia characterized by difficulty with sleep maintenance; Khedezla, a prescription medication for major depressive disorder. In addition, the company offers various generic pharmaceutical products in the areas of nutritional supplements, analgesics, urinary tract, women’s health, pre-natal vitamins, and dental health, as well as allergy, respiratory, iron deficiency, nephrology, and pain management. It serves drug wholesalers, retail drug stores, mass merchandisers, and grocery store pharmacies in the United States. The company was founded in 1996 and is headquartered in Morristown, New Jersey.

155 Employees
Last Reported Date: 03/2/15
Founded in 1996

pernix therapeutics holdings (PTX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $814.6K
Chief Financial Officer
Total Annual Compensation: $405.2K
Chief Operating Officer
Total Annual Compensation: $524.2K
Senior Vice President of Commercial Operation...
Total Annual Compensation: $300.4K
Compensation as of Fiscal Year 2014.

pernix therapeutics holdings (PTX) Key Developments

Pernix Therapeutics Holdings, Inc. Approves Appointment of Tasos G. Konidaris as Director; Approves Amendment to the Charter

Pernix Therapeutics Holdings, Inc. approved the appointment of Tasos G. Konidaris as director of the company at its AGM held on June 18, 2015. The company approved an amendment to the company’s charter to increase the number of authorized shares of capital stock at AGM held on June 18, 2015.

Pernix Therapeutics Holdings, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 11:30 AM

Pernix Therapeutics Holdings, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 11:30 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Douglas L. Drysdale, Chairman, Chief Executive Officer and President, Sanjay Patel, Chief Financial Officer.

Pernix Therapeutics's Migraine Drug Treximet Receives Expanded Approval to Paediatric Patients in US

Pernix Therapeutics has announced the US FDA expanded approval of acute migraine drug Treximet (sumatriptan + naproxen sodium) for use in paediatric patients aged between 12 and 17 years old. The priority review-designated regulatory submission was based on Phase III data that assessed the drug's safety, efficacy, and pharmacokinetic activity and demonstrated its superiority over placebo in treating migraines. The drug comes with a Boxed Warning due to the risk of cardiovascular and gastrointestinal events. The recommended dose for paediatric patients is a single tablet of Treximet 10/60 milligrammes (10 mg sumatriptan + 60 mg naproxen sodium) daily, up to a maximum dose of Treximet 85/500 mg - the daily dose for adults. The new, lower dose of Treximet will be launched on the market in the third quarter of 2015. Treximet is the first combination product to be approved for acute migraine attacks in patients under 18 years old. The two active ingredients, sumatriptan and naproxen sodium, help convey effective and sustained management of pain associated with migraines compared with treatment with just one. The FDA expedited the review process of the candidate due to the need for more treatment options for paediatric patients - an estimated 8-23% of paediatric patients aged between 11 and 17 are affected by migraines.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PTX:US $5.58 USD -0.21

PTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Interpharm Holdings Inc $0.0010 USD 0.00
OraSure Technologies Inc $5.14 USD -0.23
SciClone Pharmaceuticals Inc $11.06 USD -0.18
Sucampo Pharmaceuticals Inc $16.34 USD -0.74
Vanda Pharmaceuticals Inc $12.63 USD +0.08
View Industry Companies
 

Industry Analysis

PTX

Industry Average

Valuation PTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.6x
Price/Book 3.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PERNIX THERAPEUTICS HOLDINGS, please visit www.pernixtx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.